Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice
Ding Ai, … , Daniel J. Rader, Alan R. Tall
Ding Ai, … , Daniel J. Rader, Alan R. Tall
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1677-1687. https://doi.org/10.1172/JCI61248.
View: Text | PDF
Research Article Metabolism Article has an altmetric score of 4

Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice

  • Text
  • PDF
Abstract

Recent GWAS have identified SNPs at a human chromosom1 locus associated with coronary artery disease risk and LDL cholesterol levels. The SNPs are also associated with altered expression of hepatic sortilin-1 (SORT1), which encodes a protein thought to be involved in apoB trafficking and degradation. Here, we investigated the regulation of Sort1 expression in mouse models of obesity. Sort1 expression was markedly repressed in both genetic (ob/ob) and high-fat diet models of obesity; restoration of hepatic sortilin-1 levels resulted in reduced triglyceride and apoB secretion. Mouse models of obesity also exhibit increased hepatic activity of mammalian target of rapamycin complex 1 (mTORC1) and ER stress, and we found that administration of the mTOR inhibitor rapamycin to ob/ob mice reduced ER stress and increased hepatic sortilin-1 levels. Conversely, genetically increased hepatic mTORC1 activity was associated with repressed Sort1 and increased apoB secretion. Treating WT mice with the ER stressor tunicamycin led to marked repression of hepatic sortilin-1 expression, while administration of the chemical chaperone PBA to ob/ob mice led to amelioration of ER stress, increased sortilin-1 expression, and reduced apoB and triglyceride secretion. Moreover, the ER stress target Atf3 acted at the SORT1 promoter region as a transcriptional repressor, whereas knockdown of Atf3 mRNA in ob/ob mice led to increased hepatic sortilin-1 levels and decreased apoB and triglyceride secretion. Thus, in mouse models of obesity, induction of mTORC1 and ER stress led to repression of hepatic Sort1 and increased VLDL secretion via Atf3. This pathway may contribute to dyslipidemia in metabolic disease.

Authors

Ding Ai, Juan M. Baez, Hongfeng Jiang, Donna M. Conlon, Antonio Hernandez-Ono, Maria Frank-Kamenetsky, Stuart Milstein, Kevin Fitzgerald, Andrew J. Murphy, Connie W. Woo, Alanna Strong, Henry N. Ginsberg, Ira Tabas, Daniel J. Rader, Alan R. Tall

×

Figure 2

Restoration of sortilin-1 abolished apoB overproduction in ob/ob mice.

Options: View larger image (or click on image) Download as PowerPoint
Restoration of sortilin-1 abolished apoB overproduction in ob/ob mice.
 ...
(A) Hepatic protein expression of sortilin-1 in WT and ob/ob mice. Animals were fed WTD for 1 week before injection with control AAV8 or AAV8-Sort1, fed WTD for an additional 2 weeks, then sacrificed after a 6-hour fast. (B) TG production was determined at the indicated times after P407 injection. ANOVA revealed significant differences between treatment (F2,14 = 8.753; P = 0.0034) and time point (*P < 0.05 at 2.5 hours, Bonferroni post-test). (C) apoB levels in plasma collected at the 2.5-hour time point. (D) Quantification and ANOVA revealed significant differences between treatments for apoB100 (F2,11 = 27.91) and apoB48 (F2,11 = 5.554) from C. *P < 0.05, AAV8-Sort1 vs. control AAV8, Bonferroni post-test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 2 X users
Referenced in 5 patents
88 readers on Mendeley
See more details